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ABSTRACT
The aim of this study was to evaluate the changes in concentrations of plasma hormones after mid-
gestation termination of pregnancy with aglepristone in albino rats. Methods: Fifteen (15) pregnant albino rats 
(Rattus norvegicus) were randomly allocated to two groups. Aglepristone (Alizin®) was administered to group 
I (n = 7) subcutaneously at a dose of 10 mg/kg b.w. on days 10 and 11 of gestation (24 h apart) whereas group 
II (n = 8) were injected with an equivalent volume (0.33 mL/kg) of sterile water for injection (Dana®) via the 
same route and on the same days as indicated for group I. Blood samples for hormonal assay were collected 
from both groups and the mean serum concentrations of progesterone, oestradiol, LH and FSH on gestation 
days 8 (prior to treatment), 12, 16, and 20 were determined using the enzyme immunoassay (EIA) technique. 
Results: Bloody vulval discharges (abortion) were observed in all the aglepristone-treated rats within 24.7 ± 
3.8 h after the fi rst injection of aglepristone and lasted for 47 ± 5.7 h post-treatment. By day 16 post-mating (6 
days after fi rst treatment), the aglepristone-treated rats had signifi cantly (P<0.05) lower serum concentrations of 
oestradiol (17.07 ± 3.54 pg/mL) and progesterone (11.64 ± 4.3 ng/mL) than group II (34.19 ± 6.98 pg/mL; 88.44 
± 18.52 ng/mL respectively). By day 20 post-mating, the mean serum FSH level of group I was signifi cantly 
higher (13.61 ± 10.21 mIU/mL) than that of group II (3.84 ± 0.87 mIU/mL; P<0.05). Conclusion: Aglepristone 
was very effective in termination of pregnancy when administered mid-gestation to albino rats. However, the 
hormonal changes observed following the termination of pregnancy with aglepristone in rats differed from the 
reports in dogs and cats.
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Introduction
Specifi c approaches in endocrine research have involved the development of 
competitive hormone receptor blockers (HOFFMANN and SCHULER, 2000) which is part 
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of the global effort to develop new drugs to widen therapeutic alternatives for diseases 
and to permit better control of the oestrous cycle and fertility in general (GOBELLO, 2006). 
Antiprogestins or progesterone-antagonists are synthetic steroids that bind with great 
affi nity to progesterone receptors, competitively displacing endogenous progesterone 
and thus preventing progesterone from exerting its biological effects (HOFFMANN et 
al., 2000). Aglepristone, an analogue of mifepristone, was formulated as an injectable 
and became the fi rst antiprogestin licensed only for veterinary use (ÖZALP et al., 2008). 
The hydrophobic side chain at C17 is responsible for the high-affi nity receptor binding 
of aglepristone, while the additional aromatic ring at C11 with a dimethyl-amino group 
is responsible for the changes in receptor conformation leading to a suppression of 
transcription (HOFFMANN and SCHULER, 2000).
Due to the importance of progesterone in the maintenance of pregnancy, aglepristone 
has been applied most prominently in the prevention or termination of pregnancy in 
bitches (GALAC et al., 2000; SCHÄFER-SOMI et al., 2007) and in queens (GEORGIEV and 
WEHREND, 2006; GOERICKE-PESCH et al., 2010). Although aglepristone is marketed for 
pregnancy termination in canines, it has been used in rabbits to prevent implantation 
(ÖZALP et al., 2010) and to induce abortion (ÖZALP et al., 2008). In other reports, 
aglepristone was also used to induce parturition in dogs (FIENI et al., 2001; BAAN 
et al., 2005). Furthermore, aglepristone has been applied clinically in the treatment of 
several progesterone-related disease conditions in animals such as pyometra in cats 
(HECKER et al., 2000; NAK et al., 2009) and dogs (TRASCH et al., 2003; GÜRBULAK et 
al., 2005); hypersomatotropism in dogs (BHATTI et al., 2006); vaginal fi broma in dogs 
(ROLLÓN et al., 2008); mucometra in cats (GEORGIEV and WEHREND, 2005); mammary 
fi broadenomatosis in cats (GÖRLINGER et al., 2002; VITÁSEK and DENDISOVÁ, 2006), 
and metritis-pyometra complex in guinea pig (BARON VON ENGELHARDT, 2006).
Clinical applications of antiprogestins in humans and animals appear to be generally 
limited because of potential reproductive hazards (SPITZ, 2003; SITRUK-WARE and SPITZ, 
2003), a poor understanding of the precise mechanisms of the divergent antiprogestin 
effects on the endometrium (CHWALISZ et al., 1998; CHWALISZ et al., 2005) and a potential 
risk of increased unopposed oestrogen action leading to malignancy and other long-term 
effects as the result of prolonged use (EISINGER et al., 2003; GOPALKRISHNAN et al., 
2003). Thus our objective in this study was to evaluate the changes in concentrations 
of plasma hormones after mid-gestation termination of pregnancy with aglepristone in 
albino rats.
Materials and methods
Animals. Experiments were conducted in accordance with the regulations and ethics 
governing animal welfare and research of the University of Nigeria. Healthy albino rats 
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(Rattus norvegicus) of the Sprague-Dawley strain, comprising 15 females (12-14 weeks 
old) and 7 males (15 weeks old) were used for the study. The animals were housed in 
metallic cages at room temperature (28-32 °C) in the Laboratory Animal House of the 
Department of Veterinary Obstetrics and Reproductive Diseases, University of Nigeria 
Nsukka. Commercial feed (Vital® Growers feed, GCOML, Jos, Nigeria) and water were 
provided ad libitum for the duration of the study.
Determination of mating. The vaginal plug method as described by OCHIOGU 
et al. (2006) was used to determine successful mating in the female rats. Following the 
introduction of groups of two female rats to a male of proven fertility, vaginal wet smears 
were grossly examined every 12 hours for the presence of protein coagulates (remnants of 
the copulatory plug) as evidence of successful mating. The day of observation of vaginal 
coagulates was designated day 1 of pregnancy (ORIHUELA et al., 2009). The body weights 
of the female rats were determined on day 1 of pregnancy, and subsequently at four day 
intervals.
Induction of abortion with aglepristone. Simple randomization procedure was used 
to allocate fi fteen pregnant rats to either the test group (I) or the control group (II). 
Aglepristone (Alizin®, Virbac, Suffolk, United Kingdom) was administered to group I 
(n = 7) subcutaneously, below the loose skin over the neck, at a dose of 10 mg/kg b.w. 
on days 10 and 11 of gestation (24 h apart). Rats in group II (n = 8) were injected with 
an equivalent volume (0.33 mL/kg) of sterile water for injection (Dana®, Nigeria) via the 
same route and on the same days as indicated for the test group. The site of subcutaneous 
injection was gently massaged for a few seconds. The time of treatment was recorded 
and all the animals were placed on close observation. Abortion was determined in group 
I by physical observation of bloody vaginal discharges following aglepristone treatment.
Hormonal assay. Blood samples for hormonal assay were collected from both groups 
via the retro-orbital venous plexus on days 8 (prior to fi rst treatment), 12, 16 and 20 post-
mating. A microhaematocrit capillary tube was inserted into the medial canthus of the 
eye until the bony orbit was contacted, then withdrawn slightly to allow the blood to fl ow 
through the capillary tube into a collection test tube. Collected blood was allowed to stand 
for 30-45 min in order to coagulate and then centrifuged at 3000  g for 15 min. Following 
this, serum was aspirated from the supernatant, placed in microcentrifuge tubes and stored 
at -20 °C until analysis. The mean serum concentrations of progesterone (P4), oestradiol 
(E2), luteinising hormone (LH) and follicle-stimulating hormone (FSH) on gestation days 
8, 12, 16, and 20 were determined for both groups using the enzyme immunoassay (EIA) 
test kit (BioCheck®, USA). The absorbance was read spectrophotometrically within 15 
min with a microtitre plate reader (Teco™, USA) set at an absorption wavelength of 450 
nm. The lower limit of detection for progesterone was 0.0625 ng/mL, oestradiol (10 pg/
mL), FSH (2.5 mIU/mL) and LH (1.0 mIU/mL).
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Data Analysis. Statistical analysis was performed using SPSS software® (Version 
15.0 for Windows, SPSS Inc., Chicago, IL, USA). Mean and standard deviations (SD) 
were calculated for data groups. The serum hormone concentrations of the control and the 
aglepristone-treated groups were compared on days 8, 12, 16, and 20 of gestation using 
the Student’s t-test (two-tailed). Within-group hormone concentrations on the different 
days of gestation were analysed by One-way Analysis of Variance (ANOVA) and the 
variant means separated by the Least Signifi cance Difference (LSD) test. Values are 
expressed as mean ± SD. Results were considered signifi cant when P<0.05.
Results
Abortion. Bloody vulval discharges (abortion) were observed in all the aglepristone-
treated rats (group I) within 24.7 ± 3.8 h after the fi rst injection of aglepristone. Vaginal 
discharges lasted for 47 ± 5.7 h, during which time aborting rats often retreated to 
corners of the cages and had lowered feed intake. The rats in group II did not show any 
abnormalities in behaviour nor record any vulval discharges following treatment with the 
placebo. Rats in group II (n = 8) had normal pregnancy with an average gestation length 
of 21.3 ± 0.7 days, and delivered a mean litter size of 7.7 ± 2.0 with a litter weight of 44.0 
± 6.8 g.
Body weights and hormonal profi le after abortion. A steady increase in body weight 
was observed for rats in group II up to day 20 of gestation. However, 6 days after the fi rst 
treatment (by day 16 post-mating), the aglepristone-injected rats recorded a signifi cantly 
lower (P<0.05) group weight (175.9 ± 7.7 g) than the rats ingroup II (197.6 ± 9.3 g). 
By day 20 post-mating, group II rats weighed 231.4 ± 13.1 g while group I weighed 
signifi cantly less (177.6 ± 7.3 g; P<0.05) (Fig. 1).
Fig. 1. Mean ( ± SD) body weights of aglepristone-treated albino rats (group I) and the control 
(group II). (↑ = days of injections). * = statistically signifi cant differences at P<0.05
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Fig. 2. Mean ( ± SD) serum oestradiol (E2) concentrations of aglepristone-treated albino 
rats (group I) and the control (group II). (↑ = days of injections); * = statistically signifi cant 
differences at P<0.05
There was no signifi cant difference in the serum concentrations of E2 before treatment 
and by day 12 post-mating in group I (30.43 ± 5.91 pg/mL) and group II (25.25 ± 6.76 
pg/mL; P>0.05). However, 6 days after fi rst treatment (by day 16 post-mating), the serum 
E2 levels of the aglepristone-treated rats had decreased signifi cantly to 17.07 ± 3.54 pg/
mL when compared with group II (34.19 ± 6.98 pg/mL; P<0.05). By day 20 post-mating, 
the serum E2 level of group I was still signifi cantly lower (22.64 ± 6.54 pg/mL) than 
that of group II (63.5 ± 8.52 pg/mL; P<0.05) (Fig. 2). Serum P4 concentration was not 
signifi cantly different before treatment and by day 12 post-mating in group I (49.57 ± 
9.45 ng/mL) and group II (46.25 ± 7.74 ng/mL; P>0.05). By day 16 post-mating, the 
peripheral P4 level of the aglepristone-treated rats was signifi cantly lower (11.64 ± 4.3 ng/
mL) than that of group II (88.44 ± 18.52 ng/mL; P<0.05). By day 20 post-mating, the P4 
level of group II had decreased sharply to 27.75 ± 11.30 ng/mL but was still signifi cantly 
greater than that of group I (14.71 ± 4.86 ng/mL, P<0.05) (Fig. 3).
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Fig. 3. Mean ( ± SD) serum progesterone (P4) concentrations of aglepristone-treated albino 
rats (group I) and the control (group II). (↑ = days of injections); * = statistically signifi cant 
differences at P<0.05
Fig. 4. Mean ( ± SD) serum luteinising hormone (LH) concentrations of aglepristone-treated 
albino rats (group I) and the control (group II). (↑ = days of injections)
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Fig. 5. Mean ( ± SD) serum follicle-stimulating hormone (FSH) concentrations of aglepristone-
treated albino rats (group I) and the control (group II). (↑ = days of injections). * = statistically 
signifi cant differences at P<0.05
There was no signifi cant difference in the serum concentrations of LH before 
treatment and by day 12 post-mating in group I (2.14 ± 0.79 mIU/mL) and group II (1.89 
± 0.59 mIU/mL; P>0.05). However, 6 days after fi rst injection of aglepristone (by day 16 
post-mating), the serum LH level of group I was higher (3.97 ± 3.65 mIU/mL) than that of 
group II (1.95 ± 0.64 mIU/mL) although this was not found to be statistically signifi cant 
(P>0.05) (Fig. 4). The serum FSH concentrations showed no signifi cant differences up to 
day 16 post-mating in group I (5.83 ± 3.17 mIU/mL) and group II (3.98 ± 1.20 mIU/mL; 
P>0.05). However, by day 20 post-mating, the serum FSH level of group I was found to 
be signifi cantly higher (13.61 ± 10.21 mIU/mL) than that of group II (3.84 ± 0.87 mIU/
mL; P<0.05) (Fig. 5).
Discussion
Aglepristone injected subcutaneously was generally well tolerated in the treated rats. 
Aglepristone caused abortion in 100% of treated rats, which is consistent with reports of 
the high effi cacy of the antiprogestin in dogs (GALAC et al., 2000; SCHÄFER-SOMI et al., 
2007) and rabbits (ÖZALP et al., 2008). Other studies in cats reported lower effi cacy rates 
of 88.5% (FIENI et al., 2006) and 87% (GEORGIEV and WEHREND, 2006).
As observed in this study, mean plasma P4 concentration in the control pregnant 
rats peaked around day 16 of gestation, and began to decline rapidly around day 20 of 
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gestation, whereas E2 level increased gradually up to day 16 of gestation, but peaked 
rapidly around day 20 of gestation. These observations are in agreement with reports of 
patterns of P4 and E2 plasma concentrations in normal pregnant rats (PURI and GARFIELD, 
1982; MAGNESS, 1998; AL-BADER, 1999).
There was no signifi cant difference in P4 concentration during abortion between the 
control and aglepristone-treated rats. This observation is in agreement with reports that 
aglepristone acts as a true progesterone antagonist on the uterus, without any effect on 
luteal function in cats (FIENI et al., 2006; GEORGIEV and WEHREND, 2006), bitches (FIENI 
et al., 2001; GALAC et al., 2000) and rabbits (ÖZALP et al., 2008). Post-abortion, however, 
there was signifi cant decrease in the serum P4 levels of the aglepristone-treated rats. This 
observation is in agreement with the report in rabbits (ÖZALP et al., 2008) but differs from 
reports in bitches (GALAC et al., 2000; SCHÄFER-SOMI et al., 2007) in which serum P4 
levels remained high for up to 45 days after the beginning of abortion. Although ÖZALP 
et al. (2008) did not give any explanation for this decrease in P4 level in rabbits, we inferred 
that placental degeneration and the loss of placental luteotrophic lactogens led to the lyses 
of corpus luteum of pregnancy and the consequent fall in P4 levels in rats. Similarly, the 
loss of placentally-derived androgens required for ovarian E2 synthesis might explain the 
signifi cant decrease in serum E2 levels following abortion in the test group.
Detailed studies on the effects of progesterone receptor antagonists on the 
hypothalamic-pituitary-ovarian axis are lacking. Post-abortion, however, an increase in 
serum concentrations of LH and FSH was observed in the aglepristone-treated rats. This 
increase appears to be a consequence of the signifi cant decrease in serum E2 and P4 levels 
post-abortion, and the subsequent lack of negative feedback control on the release of 
FSH and LH in the aglepristone-treated rats. The differences in the onset and duration of 
abortion in the individual aglepristone-treated rats and the pulsatile release of LH post-
abortion might explain the variations in the serum concentrations of LH at the times of 
assay.
The decrease in feed intake during abortion, and subsequently the vaginal bleeding, 
foetal loss and decrease in P4 concentration, all contributed to the signifi cant decrease in 
weight gain in the aglepristone-treated rats as observed in this study.
In conclusion, aglepristone was very effective in termination of pregnancy when 
administered mid-gestation to albino rats. The hormonal changes observed following 
the termination of pregnancy with aglepristone in rats differed from the reports in dogs 
and cats. However, it is recommended that further investigations be carried out on 
the endocrine effects following prolonged use or repeated induction of abortions with 
aglepristone.
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SAŽETAK
Cilj istraživanja bio je procijeniti promjene u koncentraciji hormona plazme albino štakora nakon što je 
u sredini gravidnosti izazvan pobačaj aglepristonom. Petnaest gravidnih albino štakorica (Rattus norvegicus) 
razdvojeno je slučajnim izborom u dvije skupine. Aglepriston (Alizin®) je bio primijenjen u skupini I (n = 7) 
potkožno u dozi od 10 mg/kg tjelesne mase 10. i 11. dana gravidnosti (u razmaku od 24 sata) dok je skupini II (n = 
8) u iste dane i na isti način bio primijenjen volumni ekvivalent (0,33 mL/kg) sterilne vode za injekcije (Dana®). 
Uzorci krvi za određivanje hormona bili su prikupljeni od obiju skupina te je, uz pomoć imunoenzimne analize 
(EIA), 8. dana gravidnosti (prije tretmana), a zatim 12., 16. i 20. dana u serumu utvrđena srednja koncentracija 
progesterona, estradiola LH i FSH. Krvavi iscjedak iz vulve (pobačaj) ustanovljen je u svih štakorica kojima 
je dan aglepriston unutar 24,7 ± 3,8 sati od prve injekcije. Iscjedak je trajao 47 ± 5,7 sati nakon davanja. 
Šesnaestog dana nakon parenja (6 dana nakon prvog davanja), štakorice koje su dobile aglepriston imale su 
statistički značajno (P<0,05) nižu serumsku koncentraciju estradiola (17,07 ± 3,54 pg/mL) i progesterona (11,64 
± 4,3 ng/mL) u odnosu na štakorice druge skupine (34,19 ± 6,98 pg/mL; 88,44 ± 18,52 ng/mL). Do 20. dana 
nakon parenja, srednja serumska razina FSH u skupini I bila je statistički značajno viša (13,61 ± 10,21 mIU/mL) 
u odnosu na skupinu II (3,84 ± 0,87 mIU/mL; P<0,05). Zaključuje se da je aglepriston, primijenjen u srednjoj 
trećini gravidnosti, bio vrlo učinkovit za prekidanje gravidnosti albino štakorica. Ipak, hormonske promjene 
utvrđene nakon prekida gravidnosti štakorica aglepristonom, bile su različite od izvješća za pse i mačke.
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